Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.30 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25032343 | 1.00 | CA14 (0.38) | CA14SSTR4MEN1KMT2ACSNK2A2 | |
| SCHEMBL25032171 | 0.89 | CA14 (0.35) | CA14 | |
| SCHEMBL19437619 | 0.88 | CA14 (0.45) | CA14SSTR4MEN1KMT2ACSNK2A2 | |
| SCHEMBL31584056 | 0.88 | CA14 (0.45) | CA14SSTR4MEN1KMT2ACSNK2A2 | |
| SCHEMBL31618313 | 0.88 | CA14 (0.45) | CA14SSTR4MEN1KMT2ACSNK2A2 | |
| SCHEMBL23296185 | 0.87 | CA14 (0.46) | CA14SSTR4MEN1KMT2ACSNK2A2 | |
| SCHEMBL15295661 | 0.85 | CA14 (0.43) | CA14SSTR4 | |
| SCHEMBL25031989 | 0.85 | CA14 (0.43) | CA14SSTR4 | |
| SCHEMBL25756127 | 0.84 | CA14 (0.36) | CA14 | |
| SCHEMBL25032083 | 0.84 | CA14 (0.36) | CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | CA14 2124/4885SSTR4 3617/4885MEN1 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.